This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Déjà Vu All Over Again?

Daniel H. Solomon, MD, MPH; Wolfgang C. Winkelmayer, MD, ScD

JAMA. 2007;298:1216-1218.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In 2005, the US Food and Drug Administration (FDA) held an advisory committee meeting to help determine the safety of selective cyclooxygenase 2 (COX-2) inhibitors, a popular group of drugs with a novel mechanism of action but with incompletely understood effects on the cardiovascular system. Although these drugs have some potential benefits with respect to gastrointestinal toxic effects, their benefit-risk ratio was and is still unclear. Fast forward 2 years to 2007, and the FDA held a similar advisory committee meeting about the safety of rosiglitazone, a widely used thiazolidinedione (TZD) with known benefits on glycemic control but potential cardiovascular toxic effects. What have clinicians, patients, and the public learned through these recent events?

The TZDs sensitize end organs to insulin through their effect on the peroxisome proliferation–activated receptor (PPAR-). The PPAR system is a group of nuclear receptors . . . [Full Text of this Article]

Author Affiliations: Division of Pharmacoepidemiology (Drs Solomon and Winkelmayer) and Rheumatology, Immunology, and Allergy (Dr Solomon), and Renal Division (Dr Winkelmayer), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
A. Michael Lincoff, Kathy Wolski, Stephen J. Nicholls, and Steven E. Nissen
JAMA. 2007;298(10):1180-1188.
ABSTRACT | FULL TEXT  

Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Sonal Singh, Yoon K. Loke, and Curt D. Furberg
JAMA. 2007;298(10):1189-1195.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
Juurlink et al.
BMJ 2009;339:b2942-b2942.
ABSTRACT | FULL TEXT  

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
Winkelmayer et al.
Arch Intern Med 2008;168:2368-2375.
ABSTRACT | FULL TEXT  

Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease
Von Bibra et al.
Diabetes and Vascular Disease Research 2008;5:310-318.
ABSTRACT  

Glycemic Management of Type 2 Diabetes: How Tight Is Right and How to Get There
Nathan
Arch Intern Med 2008;168:2064-2066.
FULL TEXT  

Response to Letter Regarding Article, "Oxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus: Restoration by the Peroxisome Proliferator- Activated Receptor-{gamma} Agonist Rosiglitazone"
Sorrentino et al.
Circulation 2008;117:e186-e186.
FULL TEXT  

Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature
Duan et al.
Circ. Res. 2008;102:283-294.
ABSTRACT | FULL TEXT  

Thiazolidinediones and Heart Disease Risk
JWatch General 2007;2007:2-2.
FULL TEXT